Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VHB937 · 2 trials · 2 indications
The CDR is a measure of cognition and function, widely used in clinical research in AD. The scale assesses six domains: Memory, Orientation, Judgment \& Problem Solving, Community Affairs, Home \& Hobbies, and Personal Care. Based on in-depth semi-structured interview, each domain is assigned a score, which is summed to obtain the Sum of Boxes (SB) score, ranging from 0 to 18 with higher scores indicating worse condition
To compare the efficacy of VHB937 vs. placebo on a composite of permanent assisted ventilation (PAV) free survival and function in DB epoch
| Arm | Type | Description |
|---|---|---|
| VHB937 Low Dose | EXPERIMENTAL | I.V. infusions |
| VHB937 High Dose | EXPERIMENTAL | I.V. infusions |
| Placebo | PLACEBO_COMPARATOR | I.V. infusions |
| Arm 1 | EXPERIMENTAL | I.V. infusions |
| Arm 2 | PLACEBO_COMPARATOR | I.V. infusions |
| Name | Type | Description |
|---|---|---|
| VHB937 | BIOLOGICAL | VHB937 solution for infusion |
| Placebo | OTHER | Solution for infusion |
Key Inclusion Criteria * Male or female participants 50 to 85 years of age * Diagnosis of Mild Cognitive Impairment (MCI) due to AD or mild AD * Clinical Dementia Rating (CDR) Global score of 0.5 or 1.0 * Confirmation of AD based on cerebral spinal fluid (CSF) biomarkers or amyloid PET imaging * Re...